Aeterna Zentaris Inc. (AEZS)

Oncology Corporate Profile

Stock Performance

2.1789
-0.0211

HQ Location

20 Independence Blvd
Warren, NJ 7059

Company Description

Aeterna Zentaris Inc. is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer.The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options.

Website: http://www.aezsinc.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Zoptrex™ / zoptarelin doxorubicincytotoxic peptide conjugateEndometrial cancerIII
Zoptrex™ / zoptarelin doxorubicincytotoxic peptide conjugateOvarian cancerII
Zoptrex™ / zoptarelin doxorubicincytotoxic peptide conjugateProstate cancerII
AEZS-120immunotherapyProstate cancerPreclinical
AEZS-138Disorazol Z-D-Lys6-LHRH conjugateVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.aezsinc.com

Recent News Headlines

7/27/2017 12:17 pm

7/27/2017 12:17 pm

7/27/2017 12:17 pm

7/27/2017 12:17 pm

7/27/2017 12:17 pm

7/25/2017 06:17 am

7/25/2017 06:17 am

7/25/2017 06:17 am

7/25/2017 06:17 am

7/25/2017 06:17 am

7/24/2017 06:17 am

7/24/2017 06:17 am

7/24/2017 06:17 am

7/24/2017 06:17 am

7/20/2017 12:17 pm

7/20/2017 12:17 pm

7/20/2017 12:17 pm

7/20/2017 12:17 pm

7/20/2017 06:17 am

7/19/2017 12:17 pm

7/18/2017 12:17 pm

7/7/2017 06:17 am

6/30/2017 06:17 am

6/16/2017 06:17 am

6/16/2017 06:17 am